Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBT NASDAQ:PCSA NASDAQ:PHXM NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.70+3.8%$2.31$1.87▼$11.66$9.97M0.0278,236 shs54,713 shsPCSAHeatwurx$0.20+0.0%$0.21$0.15▼$1.50$10.09M1.352.26 million shs1.52 million shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AREVBRevelation Biosciences$1.58+1.3%$2.62$1.50▼$60.48$3.65M-0.04861,253 shs440,553 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare+3.85%+8.00%+18.42%-8.94%-25.71%PCSAHeatwurx+0.05%+11.57%-7.22%-17.15%-85.88%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%REVBRevelation Biosciences+1.28%-32.19%-38.76%-33.72%-96.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$2.70+3.8%$2.31$1.87▼$11.66$9.97M0.0278,236 shs54,713 shsPCSAHeatwurx$0.20+0.0%$0.21$0.15▼$1.50$10.09M1.352.26 million shs1.52 million shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AREVBRevelation Biosciences$1.58+1.3%$2.62$1.50▼$60.48$3.65M-0.04861,253 shs440,553 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare+3.85%+8.00%+18.42%-8.94%-25.71%PCSAHeatwurx+0.05%+11.57%-7.22%-17.15%-85.88%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%REVBRevelation Biosciences+1.28%-32.19%-38.76%-33.72%-96.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/APCSAHeatwurx 2.50Moderate Buy$1.00398.75% UpsidePHXMPHAXIAM Therapeutics 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest REVB, PHXM, ALBT, and PCSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$2.00 ➝ $1.008/26/2025PCSAHeatwurxZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $2.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.33M7.80N/AN/A($11.37) per share-0.24PCSAHeatwurxN/AN/AN/AN/A$0.46 per shareN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-1,451.94%N/A-75.12%11/10/2025 (Estimated)PCSAHeatwurx-$11.85M-$2.32N/AN/AN/AN/A-342.36%-243.48%10/29/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/AREVBRevelation Biosciences-$15.04M-$68.61N/AN/AN/AN/A-240.27%-148.95%11/14/2025 (Estimated)Latest REVB, PHXM, ALBT, and PCSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALBTAvalon GloboCareN/A-$2.02N/A-$6.22N/A$0.35 million8/7/2025Q2 2025PCSAHeatwurx-$0.23-$0.25-$0.02-$0.25N/AN/A8/7/2025Q2 2025REVBRevelation Biosciences-$4.46-$7.01-$2.55-$7.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.060.06PCSAHeatwurxN/A3.453.45PHXMPHAXIAM Therapeutics0.231.78N/AREVBRevelation BiosciencesN/A3.423.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%PCSAHeatwurx91.93%PHXMPHAXIAM Therapeutics0.40%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%PCSAHeatwurx2.40%PHXMPHAXIAM Therapeutics1.94%REVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare53.84 million2.41 millionNot OptionablePCSAHeatwurx2050.35 million49.14 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataREVBRevelation Biosciences102.34 million1.66 millionNot OptionableREVB, PHXM, ALBT, and PCSA HeadlinesRecent News About These CompaniesRevelation Biosciences (NASDAQ:REVB) Trading Up 1.3% - Here's What Happened4 hours ago | americanbankingnews.comRevelation Biosciences announces exercise of warrants for $9.6M in proceedsSeptember 11, 2025 | msn.comRevelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross ProceedsSeptember 11, 2025 | accessnewswire.comARevelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataSeptember 10, 2025 | accessnewswire.comAReminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataSeptember 9, 2025 | accessnewswire.comARevelation Biosciences announces topline results from PRIME studySeptember 9, 2025 | msn.comRevelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudySeptember 9, 2025 | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025August 8, 2025 | businesswire.comRevelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyJuly 16, 2025 | businesswire.comRevelation Biosciences to implement 1-for-3 reverse stock splitJuly 2, 2025 | investing.comRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025July 1, 2025 | businesswire.comRevelation Biosciences Inc News (REVB) - Investing.comJune 24, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 29, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREVB, PHXM, ALBT, and PCSA Company DescriptionsAvalon GloboCare NASDAQ:ALBT$2.70 +0.10 (+3.85%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 09/16/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Heatwurx NASDAQ:PCSA$0.20 +0.00 (+0.05%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$0.20 +0.00 (+1.25%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 09/12/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Revelation Biosciences NASDAQ:REVB$1.58 +0.02 (+1.28%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.65 +0.07 (+4.43%) As of 06:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
